In another clinical study, where 253 elderly participants with T2DM were assigned to a sitagliptin or non-sitagliptin group, reduced insulin dosage and increased Mini Mental State Exam (MMSE) scores were observed in the sitagliptin group in comparison to the non-sitagliptin group [124], indicating improved cognition with sitagliptin treatment in elderly individuals with or without AD. This evidence concerns the gene INS and Alzheimer disease.